| Literature DB >> 30271430 |
Gamil A Al-Hazmi1,2, Khlood S Abou-Melha1, Nashwa M El-Metwaly3,4, Kamel A Saleh5.
Abstract
A series of perimidine derivatives (L1-5) were prepared and characterized by IR, 1H·NMR, mass spectroscopy, UV-Vis, XRD, thermal, and SEM analysis. Five VO(II) complexes were synthesized and investigated by most previous tools besides the theoretical usage. A neutral tetradentate mode of bonding is the general approach for all binding ligands towards bi-vanadyl atoms. A square-pyramidal is the configuration proposed for all complexes. XRD analysis introduces the nanocrystalline nature of the ligand while the amorphous appearance of its metal ion complexes. The rocky shape is the observable surface morphology from SEM images. Thermal analysis verifies the presence of water of crystallization with all coordination spheres. The optimization process was accomplished using the Gaussian 09 software by different methods. The most stable configurations were extracted and displayed. Essential parameters were computed based on frontier energy gaps with all compounds. QSAR parameters were also obtained to give another side of view about the biological approach with the priority of the L3 ligand. Applying AutoDockTools 4.2 program over all perimidine derivatives introduces efficiency against 4c3p protein of breast cancer. Antitumor activity was screened for all compounds by a comparative view over breast, colon, and liver carcinoma cell lines. IC50 values represent promising efficiency of the L4-VO(II) complex against breast, colon, and liver carcinoma cell lines. The binding efficiency of ligands towards CT-DNA was tested. Binding constant (K b) values are in agreement with the electron-drawing character of the p-substituent which offers high K b values. Also, variable Hammett's relations were drawn.Entities:
Year: 2018 PMID: 30271430 PMCID: PMC6151213 DOI: 10.1155/2018/7176040
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1Synthesis of perimidine compounds 3a–e.
Figure 11H·NMR of L1 ligand (as example).
Figure 2Mass spectra of L1 and L4 ligands.
Figure 3(a) Structures of perimidine ligands (L1–5). (b) Optimized structures of five perimidine ligands.
Significant analytical and physical data of perimidine compounds and their VO(II) complexes.
| Compounds (formula weight) (calcd./found) | Color | Elemental analysis (%) calcd. (found) | ||||
|---|---|---|---|---|---|---|
| C | H | N | SO4/Cl | V | ||
| ( | Dark brown | 76.91 (76.90) | 4.65 (4.66) | 14.35 (14.35) | — | — |
| ( | Dark brown | 40.88 (40.88) | 2.74 (2.73) | 7.63 (7.65) | 26.16 (26.16) | 13.87 (13.88) |
| ( | Dark brown | 74.27 (74.27) | 4.79 (4.79) | 13.32 (13.31) | — | — |
| ( | Dark green | 39.91 (39.90) | 3.09 (3.10) | 7.16 (7.17) | 24.55 (24.54) | 13.02 (13.03) |
| ( | Dark brown | 68.96 (68.95) | 3.93 (3.93) | 16.08 (16.09) | — | — |
| ( | Dark green | 38.52 (38.52) | 2.46 (2.46) | 8.99 (8.97) | 24.65 (24.66) | 13.07 (13.05) |
| ( | Dark brown | 70.67 (70.66) | 4.03 (4.02) | 13.19 (13.18) | 8.34 (8.35) | — |
| ( | Dark green | 39.05 (39.05) | 2.49 (2.48) | 7.29 (7.28) | 24.99 (25.02)/4.61 (4.63) | 13.25 (13.26) |
| ( | Dark brown | 70.67 (70.68) | 4.03 (4.05) | 13.19 (13.18) | 8.34 (8.35) | — |
| ( | Dark brown | 37.30 (37.31) | 2.88 (2.88) | 6.96 (6.95) | 23.87 (23.88)/4.40 (4.41) | 12.66 (12.67) |
Significant IR spectral bands (cm−1) of perimidine compounds and their VO(II) complexes.
| Compounds |
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| ( | 3155 | 1473 | 1618 | 1518 | — | — | — | — | — | — |
| ( | 3110, 3350 | 1470 | 1596 | 1514 | 1420 | 1142 | 765, 670 | 966 | 588 | 476 |
| ( | 3177 | 1470 | 1597 | 1508 | —- | — | — | — | — | — |
| ( | 3100, 3372 | 1447 | 1592 | 1502 | 1411 | 1146 | 765, 697 | 1074 | 572 | 515 |
| ( | 3150 | 1473 | 1620 | 1538 | — | — | — | — | — | — |
| ( | 3105, 3382 | 1447 | 1616 | 1517 | 1411 | 1179 | 743, 697 | 966 | 600 | 508 |
| ( | 3160 | 1474 | 1614 | 1518 | — | — | — | — | — | — |
| ( | 3100, 3420 | 1471 | 1624 | 1510 | 1434 | 1150 | 755, 637 | 985 | 610 | 550 |
| ( | 3150 | 1473 | 1620 | 1518 | — | — | — | — | — | — |
| ( | 3054, 3384 | 1446 | 1616 | 1512 | 1368 | 1140 | 754, 689 | 1074 | 589 | 508 |
Electronic transitions of perimidine compounds and their VO(II) complexes.
| Compounds |
| d-d transition bands (cm−1) | Intraligand and charge transfer (cm−1) |
|---|---|---|---|
| ( | — | — | 31,746; 26,316; 23,923; 18,868 |
| ( | 1.66 | 15,290; 12800 | 35,714; 29,412; 25,641; 24,272; 17,857 |
| ( | — | — | 38,168; 28,249; 23,810; 19,048 |
| ( | 1.68 | 15,393; 12750 | 37,037; 30,769; 26,316; 23,256; 17,544 |
| ( | — | — | 36,364; 30,303; 26,316; 23,810; 19,157 |
| ( | 1.66 | 15,873; 12830 | 37,037; 28,571; 26,667; 18,182 |
| ( | — | — | 31,746; 25,974; 18,587 |
| ( | 1.67 | 15,385; 12,800 | 35,714; 30,303; 25,974; 24,390; 17,857 |
| ( | — | — | 31,250; 26,316; 24,390; 18,182 |
| ( | 1.65 | 15,873; 12780 | 35,714; 30,769; 25,000; 23,256; 18,868 |
Figure 4Geometry optimization of VO(II)-perimidine complexes (a–e, respectively).
Figure 5ESR spectrum of L1 + VO(II)complex.
Spin Hamiltonian parameters of all VO(II) complexes (A and p x10−4).
| Complex |
|
|
|
|
|
|
|
|
|
|
2
|
2
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ( | 1.93 | 1.96 | 1.95 | 167 | 115.57 | 66 | 99.67 | 1.71 | 117.52 | 0.796 | −0.843 | −1.981 | 1.959 | 0.9357 |
| ( | 1.94 | 1.97 | 1.96 | 170 | 114.12 | 71 | 104.00 | 1.93 | 115.19 | 0.861 | −0.724 | −1.512 | 1.490 | 0.9435 |
| ( | 1.92 | 1.96 | 1.95 | 168 | 114.28 | 69 | 105.67 | 1.95 | 115.19 | 0.865 | −0.961 | −1.985 | 1.964 | 0.9243 |
| ( | 1.94 | 1.98 | 1.97 | 171 | 113.45 | 73 | 105.67 | 2.79 | 114.00 | 0.895 | −0.727 | −1.055 | 1.033 | 0.9395 |
| ( | 1.93 | 1.97 | 1.96 | 171 | 112.86 | 72 | 105.00 | 2.24 | 115.19 | 0.869 | −0.841 | −1.515 | 1.494 | 0.9318 |
Figure 6X-ray diffraction pattern of high crystalline ligand.
Estimated TG data of perimidine compounds and all VO(II) complexes.
| Compound | Steps | Temp. range (°C) | Decomposed | Weight loss; calcd. (found %) |
|---|---|---|---|---|
| L1 | 1st | 45.1–120.5 | -[C6H6 + N2] | 27.18 (27.16) |
| 2nd | 122.2–410.1 | -[C6H5 + CO] | 26.92 (26.95) | |
| 3rd | 410.3–670.2 | -[C8H7N2] | 33.59 (33.54) | |
| Residue | 4C | 12.31 (12.35) | ||
| [(VO)2 (SO4)2 (L1)]H2O | 1st | 80.3–120.3 | -[H2O + SO4] | 15.53 (15.55) |
| 2nd | 120.6–391.7 | -[SO4 + C6H6 + N2] | 27.53 (27.55) | |
| 3rd | 391.9–798.8 | -[C19H12N2] | 36.53 (36.50) | |
| Residue | V2O3 | 20.41 (20.40) | ||
| L2 | 1st | 65.6–156.1 | -[C6H5OCH3] | 25.72 (25.71) |
| 2nd | 156.6–299.9 | -[C6H5 + CO + N2] | 31.66 (31.69) | |
| 3rd | 301.0–663.2 | -[C9H7N2] | 34.05 (33.89) | |
| Residue | 3C | 8.57 (8.71) | ||
| [(VO)2 (SO4)2 (L2)]2H2O | 1st | 42.1–135.1 | -[2H2O + 2SO4] | 29.16 (29.16) |
| 2nd | 136.1–270.1 | -[C6H5OCH3 + N2] | 17.40 (17.29) | |
| 3rd | 271.0–485.4 | -[C6H5] | 9.85 (9.94) | |
| 4th | 485.6–797.9 | -[C13H7N2] | 24.43 (24.45) | |
| Residue | V2O3 | 19.15 (19.16) | ||
| L3 | 1st | 63.66–230.51 | -[C6H6 + NO2] | 28.50 (27.90) |
| 2nd | 231.21–410.11 | -[C7H5 + CO + N2] | 33.33 (33.31) | |
| 3rd | 410.52–650.64 | -[C11H6N2] | 38.16 (38.79) | |
| [(VO)2 (SO4)2 (L3)]H2O | 1st | 79.2–140.6 | -[H2O + SO4] | 14.63 (14.62) |
| 2nd | 141.9–278.9 | -[SO4 + C6H5 + CO] | 25.81 (25.78) | |
| 3rd | 279.1–479.5 | -[NO2 + C6H6 + N2] | 19.52 (19.53) | |
| 4th | 480.11–798.8 | -[C12H6N2] | 22.86 (22.90) | |
| Residue | V2O2 | 17.18 (17.17) | ||
| L4 | 1st | 64.65–145.46 | -[C6H5Cl + CO + N2] | 39.68 (39.68) |
| 2nd | 145.68–326.78 | -[C6H5 + N2] | 24.74 (24.75) | |
| 3rd | 330.12–680.23 | -[C12H7] | 35.58 (35.57) | |
| [(VO)2 (SO4)2 (L4)]H2O | 1st | 69.1–256.1 | -[H2O + C6H5Cl + SO4] | 29.48 (29.65) |
| 2nd | 256.9–484.1 | -[SO4 + CON2 + C6H5] | 29.80 (29.81) | |
| 3rd | 484.6–789.4 | -[C10H7N2] | 20.18 (19.98) | |
| Residue | V2O2 + 2C | 20.54 (20.56) | ||
| L5 | 1st | 62.3–169.6 | -[C6H5 + N2] | 24.74 (24.71) |
| 2nd | 160.1–371.9 | -[C6H5Cl + CO + N2] | 39.68 (39.59) | |
| 3rd | 372.6–666.8 | -[C9H7] | 27.10 (27.19) | |
| Residue | 3C | 8.48 (8.51) | ||
| [(VO)2 (SO4)2 (L5)]3H2O | 1st | 42.1–266.3 | -[3H2O + C6H5Cl] | 20.70 (20.71) |
| 2nd | 266.38–482.5 | -[2SO4 + CON2 + C6H5] | 40.41 (40.61) | |
| 3rd | 482.9–793.5 | -[C8H7N2] | 16.29 (16.36) | |
| Residue | V2O2 + 4C | 22.60 (22.32) |
Figure 7Hammett's relation between the effect of p-substituent (σR) and intrinsic binding constants (K b) of the ligands.
Figure 8(a) Frontier molecular orbitals of HOMO(1)and LUMO(2) pictures of perimidine ligands. (b) Frontier molecular orbitals of HOMO(1) and LUMO(2) pictures of VO(II)-perimidine complexes (A–E, respectively).
Energy parameters (eV) using the DFT/B3LYP method of optimized structures.
| Compound |
|
| ( |
|
|
|
|
|
| ϭ |
|---|---|---|---|---|---|---|---|---|---|---|
| L1 | −0.17417 | −0.07574 | −0.0984 | 0.09843 | 0.124955 | −0.12496 | 0.049215 | 0.024608 | 0.158628 | 20.31900843 |
| L1 + VO(II) | −0.20433 | −0.19545 | −0.0089 | 0.00888 | 0.19989 | −0.19989 | 0.00444 | 0.00222 | 4.499551 | 225.2252252 |
| L2 | −0.17142 | −0.07426 | −0.0972 | 0.09716 | 0.12284 | −0.12284 | 0.04858 | 0.02429 | 0.155307 | 20.58460272 |
| L2 + VO(II) | −0.20163 | −0.19237 | −0.0093 | 0.00926 | 0.197 | −0.197 | 0.00463 | 0.002315 | 4.191037 | 215.9827214 |
| L3 | −0.21252 | −0.05654 | −0.156 | 0.15598 | 0.13453 | −0.13453 | 0.07799 | 0.038995 | 0.11603 | 12.82215669 |
| L3 + VO(II) | −0.21881 | −0.21008 | −0.0087 | 0.00873 | 0.214445 | −0.21445 | 0.004365 | 0.002183 | 5.267658 | 229.0950745 |
| L4 | −0.25291 | −0.05654 | −0.1964 | 0.19637 | 0.154725 | −0.15473 | 0.098185 | 0.049093 | 0.121912 | 10.18485512 |
| L4 + VO(II) | −0.20433 | −0.19545 | −0.0089 | 0.00888 | 0.19989 | −0.19989 | 0.00444 | 0.00222 | 4.499551 | 225.2252252 |
| L5 | −0.17808 | −0.0842 | −0.0939 | 0.09388 | 0.13114 | −0.13114 | 0.04694 | 0.02347 | 0.183188 | 21.30379207 |
| L5 + VO(II) | −0.19719 | −0.16607 | −0.0311 | 0.03112 | 0.18163 | −0.18163 | 0.01556 | 0.00778 | 1.060073 | 64.26735219 |
Figure 9Hammett's relation between the effect of p-substituent (σR) and energy gaps (δE) of ligands and their VO(II) complexes.
Considerable bond lengths, charges, dipole moment (D), oscillator strength (ʄ), and excitation energies (E).
| Compound | O19 | N11 | N15 | N16 | C18–O19 | C12–N11 | C14–N15 | N15–N16 | V1 | V2 |
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L1 | −0.415473 | −0.555221 | −0.349927 | −0.275635 | 1.224561 | 1.384229 | 1.287795 | 1.366391 | — | — | 5.1769 | 567.81 | 0.0316 |
| L1 + VO(II) | −0.410181 | −0.282766 | −0.316313 | −0.248429 | — | — | — | — | 0.933201 | 0.929331 | 11.5667 | 16513.7 | 0.003 |
| L2 | −0.410237 | −0.555363 | −0.348134 | −0.275746 | — | — | — | — | — | — | 6.4963 | 576.26 | 0.0403 |
| L2 + VO(II) | −0.420038 | −0.397120 | −0.322648 | −0.250261 | — | — | — | — | 0.927552 | 0.915069 | 3.5504 | 31387.7 | 0.0008 |
| L3 | −0.416751 | −0.044378 | −0.050930 | 0.113237 | 1.317259 | 2.076019 | 1.772715 | 1.281712 | — | — | 5.3595 | 7613.39 | 0.002 |
| L3 + VO(II) | −0.414856 | −0.387699 | −0.320321 | −0.254947 | 0.955124 | 0.952544 | 16.6899 | 17266.3 | 0.0032 | ||||
| L4 | −0.313357 | −0.358945 | −0.031267 | −0.294059 | 1.223609 | 1.404653 | 1.286454 | 1.367672 | — | — | 4.4684 | 315.92 | 0.4055 |
| L4 + VO(II) | −0.410181 | −0.282766 | −0.316313 | −0.248429 | — | — | — | — | 0.933201 | 0.929331 | 11.5667 | 16513.7 | 0.003 |
| L5 | −0.354631 | −0.480428 | −0.209492 | −0.312115 | 1.224058 | 1.384450 | 1.286411 | 1.367122 | — | — | 3.9661 | 600.17 | 0.043 |
| L5 + VO(II) | −0.405024 | −0.408894 | −0.304735 | −0.210573 | — | — | — | — | 0.905245 | 0.730601 | 8.9706 | 20988.6 | 0.002 |
QSAR computation for optimized structures of perimidine compounds.
| Function | L1 | L2 | L3 | L4 | L5 |
|---|---|---|---|---|---|
| Surface area (approx.) (Å2) | 425.73 | 488.36 | 496.79 | 464.04 | 465.53 |
| Surface area (grid) (Å2) | 623.02 | 661.15 | 661.91 | 644.29 | 642.82 |
| Volume (Å3) | 1060.57 | 1138.87 | 1134.04 | 1105.99 | 1105.72 |
| Hydration energy (kcal/mol) | −8.29 | −9.97 | −17.83 | −8.00 | −8.02 |
| Log P | 2.53 | 1.53 | −1.64 | 2.31 | 2.31 |
| Reactivity (Å3) | 132.87 | 139.25 | 138.92 | 137.59 | 137.59 |
| Polarizability (Å3) | 45.32 | 47.80 | 47.62 | 47.25 | 47.25 |
| Mass (amu) | 390.44 | 420.47 | 436.45 | 424.89 | 424.89 |
Docking energy values (kcal/mol) of perimidine compounds (HL) and protein receptors complexes.
| Ligands | p | Receptor | Est. free energy of binding | Est. inhibition constant ( | vdW + bond + desolving energy | Electrostatic energy | Total intercooled energy | Frequency | Interacting surface |
|---|---|---|---|---|---|---|---|---|---|
| L1 | 10.96 | 4c3p | −7.92 | 1.57 | −9.29 | −0.06 | −9.34 | 30% | 859.778 |
| 3bch | +355.37 | — | +349.42 | +0.06 | +349.48 | 10% | 665.36 | ||
| 4zdr | −4.72 | 345.45 | −5.97 | −0.05 | −6.02 | 20% | 723.695 | ||
| L2 | 10.96 | 4c3p | −7.75 | 2.09 | −9.13 | −0.13 | −9.26 | 10% | 983.377 |
| 3bch | +490.76 | — | +473.39 | +0.00 | +473.39 | 10% | 662.71 | ||
| 4zdr | −4.32 | 686.85 | −5.97 | −0.02 | −5.99 | 20% | 758.018 | ||
| L3 | 10.95 | 4c3p | +647.56 | — | +644.74 | +0.01 | +644.75 | 10% | 718.318 |
| 3bch | +709.10 | — | +699.61 | −0.05 | +699.56 | 10% | 661.43 | ||
| 4zdr | −4.66 | 385.21 | −6.46 | +0.07 | −6.39 | 10% | 621.389 | ||
| L4 | 10.96 | 4c3p | −7.28 | 4.62 | −8.57 | −0.03 | −8.60 | 20% | 929.747 |
| 3bch | +552.25 | — | +549.59 | −0.03 | +549.56 | 30% | 710.605 | ||
| 4zdr | −4.67 | 376.04 | −6.13 | −0.19 | −6.32 | 20% | 595.541 | ||
| L5 | 10.95 | 4c3p | −8.41 | 683.74 | −9.81 | −0.00 | −9.81 | 20% | 925.161 |
| 3bch | +663.87 | — | +661.94 | +0.01 | +661.95 | 10% | 703.598 | ||
| 4zdr | −4.84 | 284.49 | −6.39 | +0.04 | −6.35 | 10% | 690.838 |
Figure 10Interacting protein-inhibitor complexes (a) L1, (b) L2, (c) L3, (d) L4, and (e) L5 with 4zdr receptor (a–e, respectively).
Figure 11Interacting complexes hp plot for (a) L1, (b) L2, (c) L3, (d) L4, and (e) L5 with 4zdr receptor (a–e, respectively).
IC50 of some tested compounds against liver (HepG2), breast (MCF-7), and colon (HCT116) cancer cell lines.
| Cell type | IC50 ( | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| L1 | VO(II)-L1 | L2 | VO(II)-L2 | L3 | VO(II)-L3 | L4 | VO(II)-L4 | L5 | VO(II)-L5 | Doxorubicin | |
| MCF-7 | 19.68 | 23.06 | 25.92 | 93.92 | 15.50 | >100 | 24.96 | 3.42 | 11.44 | >100 | 0.60 |
| HepG2 | 19.79 | 19.94 | 27.23 | 55.67 | 11.01 | >100 | 28.25 | 1.27 | 9.91 | >100 | 0.34 |
| HCT116 | 19.15 | 22.93 | 13.27 | 95.17 | 15.53 | >100 | 26.24 | 1.66 | 23.30 | >100 | 0.39 |
Figure 12Dose response curves of perimidine ligands against MCF-7 (a), HCT116 (b), and HepG2 (c) cancer cells.